Navigation path

FP7 Calls

TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES: TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH

2.3.2. HIV/AIDS, malaria and tuberculosis

The focus will be on developing new therapies, diagnostic tools, and preventive tools such as vaccines. Research efforts will confront the three diseases at global level, but will also address specific European aspects of the three diseases. Preclinical and early clinical research activities will be emphasised, and where relevant collaboration with European and global initiatives is foreseen. Note: for topics under this area applicants will have to follow the rules for single-stage submission procedure (see respective call fiche in section III).

HEALTH.2010.2.3.2-1: Target characterisation and hit-to-lead progression in tuberculosis (TB) Drug development. FP7-HEALTH-2010-single-stage.

In this research, genetic and chemical approaches should be utilised to identify and validate TB drug targets in the form of a single collaborative project, which brings together a critical mass of partners from public and private sectors. Research should concentrate on the target-to-hit phase and contribute to filling the pipeline of new TB drug candidates with the potential of shortening treatment and being effective against multidrug-resistant TB. Hit-to-lead progression should be done effectively by academics and partnering industry. Essential elements of the project could include assay development, structural biology, virtual screening, high-throughput screening, fragment-based screening and rational drug design. Participation of partners from Eastern Europe and Central Asia (EECA) could increase the impact of this project and will be considered in the evaluation of the proposal. Active participation of SMEs could lead to an increased impact of the research proposed and this will be considered in the evaluation of the proposal.

Note: Limits on the EC financial contribution apply. These are implemented strictly as formal eligibility criteria. You must refer to the call fiche for details of these limits.

Funding scheme: Collaborative project (Large-scale integrating project)
EC contribution per project: min. EUR 6 000 000 – max. EUR 12 000 000
Only up to one proposal can be selected.
Expected impact: European scientists have already achieved good results with early discovery of targets for TB drug candidates. Genomic information and structural data banks are available already, but the European know-how could be better integrated to make advances in the field towards new hits and leads. Eastern Europe is particularly strong in this area and their participation will have a structural effect on European TB Drugs field. Preparedness for controlling spreading of the multidrug resistant forms of TB will be increased, since efforts will be made to develop new classes of drugs which have the potential of shortening the current standard treatment and to be effective against multi drug-resistant (MDR-TB) and extensively drug-resistant TB (XDR-TB). Overall strength to the TB drug pipeline will be sought.

HEALTH.2010.2.3.2-2: Lead optimisation and late preclinical development in TB drugs. FP7-HEALTH-2010-single-stage.

Preclinical studies in TB drug development are requested. Research should aim at optimising the drug-like properties of lead compounds and generate a pharmacological, safety and biopharmaceutical profile of the compounds. Projects are expected to take at least one lead compound closer to clinical phase. In addition, to lead optimization, the project could contain other elements of late pre-clinical and/or early clinical development, such as manufacturing information and clinical protocols. Active involvement of industry, especially SMEs and/or Product Development Public-Private Partnership organisations, could lead to an increased impact on the research proposed, and this will be considered in the evaluation of the proposal. Note: Limits on the EC financial contribution apply. These are implemented strictly as formal eligibility criteria. You must refer to the call fiche for details of these limits.

Funding scheme: Collaborative project (Small or medium-scale focused research project)
EC contribution per project: max EUR 6 000 000
One or more proposals can be selected.
Expected impact: The expected impact is enhanced output of research results essential for the development of new drugs against tuberculosis. This topic emphasises translational research supporting development of more efficient drugs against tuberculosis. This also provides a possibility to strengthen the European competitiveness in this area and to help to maintain the strong research momentum which has delivered promising results in FP6. The integration of expertise from public and private institutions will be an extra asset in this area, and the involvement of research groups from Eastern Europe will strengthen the impact.

HEALTH.2010.2.3.2-3. European network of cohort studies on HIV/AIDS. FP7- HEALTH-2010-single-stage.

The aim is to present an integrated pan-European network of cohort studies involving HIV-infected patients, including migrant populations, injection drug users, and men who have sex with men. Main goals should include improving diagnosis and prognosis of patients infected with HIV, understanding mechanisms of non-progression to disease, advancing understanding of pathogenesis (especially immunopathogenesis) of the HIV infection, studying the epidemiology of different HIV subtypes in Europe (including Eastern Europe), combating mother to child transmission of HIV, and proposing new interventions against the infection. The Network should be able to efficiently coordinate multi-disciplinary efforts to prevent and treat HIV infection in Europe, both in adults and children. The inclusion of cohorts of patients with HIV-related co-infections will be considered as an asset. The proposed Network of Excellence (NoE) should provide a rationally organised joint programme of activities to implement common research goals and strategies, common research platforms and technologies, as well as standardised methods and protocols. Integration activities will furthermore comprise joint multidisciplinary training schemes and a concrete dissemination plan. The NoE should aim to create durable joint structure (e.g. forming part of a virtual European research institute) to promote stronger institutional integration between core partners of the network, with the aim of structuring the European Research Area in the field. Active participation of SMEs and/or Product Development Public-Private Partnership organisations could lead to an increased impact of the research proposed, and this will be considered in the evaluation of the proposal.

Note: Limits on the EC financial contribution apply. These are implemented strictly as formal eligibility criteria. You must refer to the call fiche for details of these limits.
Funding scheme: Network of Excellence
EC contribution per project: max. EUR 12 000 000
Only up to one proposal can be selected.
Expected impact: Grouping all main European cohorts under a single NoE will allow construction of larger multi-cohort collaborations providing a higher statistical power, and will hence offer more robust prevention and treatment guidelines and a better public health impact. Moreover, the creation of a single network will allow the construction of an amalgamated single dataset to address key questions of direct relevance to infected populations. Finally, from a managerial point of view, a single network will ensure that resources are maximized in comparison to many different small, uncoordinated cohorts.

For more information